Exosome Mediated Pathological Protein Propagation plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Exosome Mediated Pathological Protein Propagation is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Exosomes are small extracellular vesicles (30-150 nm) that facilitate intercellular communication by transferring proteins, lipids, RNA, and DNA between cells. In neurodegenerative diseases, exosomes play a critical role in the spreading of pathological proteins across neural circuits, enabling prion-like propagation of protein aggregates from cell to cell.
| Component | Function | Disease Relevance |
|---|---|---|
| ESCRT Complex | MVB formation, ILV budding | Tethering/sorting |
| Alix | ESCRT accessory protein | Exosome loading |
| TSG101 | ESCRT-I component | Cargo selection |
| CD63/CD81/CD9 | Tetraspanins | Exosome markers |
| HSP70/HSP90 | Chaperones | Protein loading |
| nSMase2 | Ceramide generation | Exosome release |
Pathological protein accumulation
Exosome cargo
Aβ Exosomal Spread
Tau Propagation
Evidence
α-Synuclein Transmission
Microglial Exosomes
Evidence
TDP-43 Pathology
C9orf72 DPR
SOD1, FUS
| Strategy | Compound/Mechanism | Stage |
|---|---|---|
| nSMase2 inhibitors | GW4869, DAPT | Preclinical |
| HSP90 inhibitors | Geldanamycin | Research |
| Calcium channel blockers | Amlodipine | Research |
| Rab GTPase inhibitors | Dacrylation | Research |
| Strategy | Target | Stage |
|---|---|---|
| Antibodies | Surface proteins | Clinical trials |
| Peptide blockers | Heparan sulfate | Preclinical |
| Receptor antagonists | Integrins | Research |
Exosomal proteins serve as disease biomarkers:
| Disease | Exosomal Marker | Utility |
|---|---|---|
| AD | Aβ42, p-tau181, p-tau217 | Diagnostic |
| PD | α-syn oligomers | Diagnostic |
| ALS | TDP-43, SOD1 | Diagnostic |
Exosome-mediated propagation intersects with:
Exosome Mediated Pathological Protein Propagation plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Exosome Mediated Pathological Protein Propagation has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
1.顶 Selkoe DJ. Transneuronal propagation of neurodegenerative pathology. Nat Neurosci. 2014;17(9):1224-1232.
2.顶 Lee SJ, et al. Exosome-mediated spread of protein aggregates in neurodegeneration. Exp Neurobiol. 2020;29(1):4-12.
3.顶 Vingtdeux V, et al. Exosomes in neurodegeneration. Nat Rev Neurol. 2012;8(11):620-634.
4.顶 Guo M, et al. MicroRNA in exosomes: key players in neurodegeneration. Front Cell Neurosci. 2022;16:842439.
5.顶 Mathews PM, Levy E. Exosome production and its implications for Alzheimer's disease. J Prev Alzheimers Dis. 2019;6(4):269-274.
6.顶 Emmanouilidou E, et al. Cell-produced alpha-synuclein is released in exosomes. J Neurosci. 2010;30(45):15077-15087.
7.顶 Saman S, et al. Exosome-associated tau is secreted in vivo. J Biol Chem. 2012;287(6):3842-3849.
8.顶 Silverman JM, et al. Neuronal exosomes in Alzheimer's disease. Neurobiol Aging. 2016;42:138-147.
9.顶非 iguchi K, et al. Exosome-mediated spread of tau pathology. Cell Rep. 2013;5(5):1186-1193.
10.顶 Tsunemi A, et al. Exosomes and their pathophysiology in neurodegenerative diseases. J Neurochem. 2018;145(4):263-274.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 0 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 30%